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Summary points
• According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2018,
an estimated 37.9 million people were living with HIV worldwide. There were also 1.7
million new infections and 770,000 deaths.
• At the end of June 2019, 24.5 million people were receiving antiretroviral therapy
(ART). Nonetheless, increased access to high-quality ART services is needed to further
reduce mortality and new infections and to optimize long term outcomes.
• In this article, we summarize priorities for HIV service delivery research and guidance
identified through a World Health Organization (WHO) consultation held at the end of
2018.
• The priorities identified include linkage from HIV testing to care; rapid initiation of
ART (including out-of-facility ART initiation); task sharing and decentralization,
including children and patients on second line; ART delivery for stable clients; adher-
ence, retention, and reengagement in care; management of advanced HIV disease; pro-
vision of welcoming health services; and strengthening of service integration,
particulary for NCDs and family planning.
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• Ongoing evaluation is needed to determine the net effects of introducing differentiated
service delivery models, in terms of health service inputs and long-term outcomes for
people living with HIV.
Introduction
To support delivery of antiretroviral therapy (ART) at scale, the World Health Organization
(WHO) has promoted a public health approach to HIV treatment and care. Recognizing the
critical importance of streamlined, standardized approaches to scaling up HIV services in set-
tings with limited resources, the public health approach emphasizes strategies such as task
sharing, decentralization and integration of HIV services with other public health programs,
and patient and community empowerment. The public health approach also prioritizes
streamlined clinical and laboratory monitoring, standardized first- and second-line treatment
regimens, and harmonized monitoring and evaluation strategies [1,2]. In high-income coun-
tries with more resources and fewer HIV cases a more individualized approach to HIV care is
favored, although the overarching framework of the public health approach provides the set-
ting within which this more personalized service delivery can occur.
Since 2013, WHO has developed evidence-based recommendations aimed at addressing
the key steps in the HIV care cascade from HIV testing and linkage to care to initiation of
ART and adherence and retention [3]. WHO’s public health approach includes differentiated
service delivery, which tailors delivery strategies to specific populations to optimize quality,
satisfaction, and efficiency [4]. By responding to patient preferences, needs, and values, differ-
entiated service delivery improves the quality of health systems [5,6].
Methods
In November 2018, WHO held an expert consultation on future priorities for HIV treatment
service delivery. The consultation included national HIV program managers from 11 coun-
tries, implementation partners, and representatives from civil society and academia. To sup-
port this consultation, WHO conducted a survey to assess the implementation status of
current guideline recommendations (S1 Text). Information on the implementation status of
service delivery recommendations was accessed from the Joint United Nations Programme on
HIV/AIDS (UNAIDS) database http://lawsandpolicies.unaids.org/.
We discuss the findings of the consultation for implementing key service delivery interven-
tions and priorities for future guidance (Table 1). Priorities for future guidance have been
grouped according to the HIV care cascade: linkage from HIV testing to care; initiating and
maintaining ART; adherence, retention, and reengagement in care; managing advanced HIV
disease; and service integration.
Barriers to access to care, although critical, are beyond the scope of this review.
Results
Linkage from HIV testing to care
Globally, only 65% of HIV-positive individuals are receiving ART, and the proportion of HIV-
negative individuals at high risk of HIV acquisition who have access to HIV prevention ser-
vices is unknown [7]. Approximately a quarter of people living with HIV are unaware of their
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status; thus, a strategic mix of testing approaches is recommended, including facility-based
and community-based testing strategies, self-testing, and assisted partner notification [8].
There is a renewed emphasis on ensuring that HIV testing is coupled with effective linkage to
treatment and combination prevention services, supported by research and policies that pro-
mote starting treatment as soon as possible after an HIV-positive diagnosis is confirmed [9–
11].
Updated WHO HIV testing guidelines, including recommendations on linkage to care,
were released in December 2019. These guidelines emphasize that wherever HIV testing is pro-
vided, the person or organization doing the testing should be responsible for supporting clients
and linking them to treatment and prevention services [12]. Effective linkage is particularly
important when testing occurs outside of health facilities [13]. Current WHO guidelines
emphasize several options for supporting timely linkage to care, including peer support and
navigation, service integration (i.e., starting treatment across health services) and tracing of
Table 1. Evolution of HIV service delivery guidance.
Issue Current guidance Additional guidance needed
Linkage from HIV testing
to care and prevention
Peer support and navigation, service integration, and tracing. Phased strategies of testing distribution and linkage through peers.
Linkage to prevention.
Rapid ART initiation Within 7 days with the offer of same-day ART. Cointerventions that maximize treatment outcomes following rapid
ART initiation, contextual factors that could influence success of
such cointerventions.
Minimum counseling intervention required prior to and after same-
day ART.
Guidance on timing of ART initiation for settings with differing








Peer counseling, mobile text messaging, reminder devices, CBT,
behavior skills training, fixed-dose combinations.
Optimal approach to measuring adherence, especially as patients in
less intense models of care have less interaction with the healthcare
system. Timing and frequency of interventions, healthcare worker
attitude, patient experience.
Peer support, adherence clubs, and extra care for high-risk
people.
Role of peers (adolescents and key populations).
Tracing and return to care None. Interventions to support tracing (including frequency and methods)




Nurse initiation of ART. Nurse initiation of ART including for children and regimen change.
Lay-worker provision of certain essential diagnostic tests. Defined list of diagnostic tests that can be provided by lay workers
with emphasis on the importance of using the result to change
patient management.
Frequency of clinic visits
and drug refills




Reduced clinic visits for stable clients, package of care for
advanced HIV disease.
Narrowing the choice of different models for stable clients (stable
adults, children and adolescents, pregnant and breastfeeding women,
key populations).
Service integration HIV and TB treatment, ART provision where opioid substitution
therapy is provided, integration of sexually transmitted infections
and family planning services within HIV care settings, assessment
and management of cardiovascular risk and depression.
HIV and noncommunicable diseases and sexual and reproductive
health.
Provider attitudes None. Good practices to promote approachable and welcoming services.
ART, antiretroviral therapy; CBT, cognitive behavioral therapy; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1003028.t001
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individuals who are not successfully linked [4]. Consideration of resources required for each
approach could help prioritize future interventions.
Another potential strategy is to initiate ART in the community and then refer patients to
the health facility for follow-up. A study from Lesotho found that people offered same-day
ART start at home were more likely to link to care following an HIV-positive diagnosis than
those referred to a health facility to initiate ART [14].
Rapid initiation of ART
Research and program experience has shown that losses to care prior to starting ART can be
reduced by reducing time to ART initiation [15,16]. WHO recommends rapid initiation of
ART within 7 days following a confirmed HIV diagnosis and the offer of same-day ART initia-
tion for those who are ready [17]. These recommendations have been adopted by most coun-
tries surveyed (S2 Text).
Rapid initiation of ART, including starting ART on the same day as HIV diagnosis, can
lead to improved retention in care and increased viral suppression [18]. Concern regarding
the possible risk of immune reconstitution inflammatory syndrome among people starting
ART with advanced immunosuppression may lead to a delayed ART initiation. To minimize
this risk, programs could improve baseline screening for advanced HIV disease, including
tests to rapidly identify and treat, or exclude, active tuberculosis (TB) and cryptococcal menin-
gitis without delaying ART initiation for most patients [19].
Some program reports suggest an increased risk of loss to care following ART initiation,
highlighting the importance of focusing attention on adherence challenges during the initial
period following ART initiation [16]. This is underscored by findings that good adherence in
the initial months after starting ART initiation is predictive of long-term treatment success
[20,21]. Ensuring that individuals receive adequate information to make an informed decision
to start treatment is particularly important in the context of rapid ART initiation and same-
day ART start.
Guidance is needed to identify the type, frequency, and duration of interventions that can
improve treatment outcomes following rapid ART initiation, particularly for asymptomatic
patients.
Out-of-facility ART initiation
Community-based testing and rapid ART initiation have been implemented in several coun-
tries, but support is needed to ensure that ART is safely and successfully started outside of
health facilities. A trial from Malawi found that more people started ART at home than those
referred to a health facility [22]. Another trial, from Lesotho, found that more patients initiat-
ing same-day ART achieved viral suppression at 12 months (50%) than those referred to health
centers (34%); acceptance of same-day ART on the same day was high, with 98% of patients
indicating readiness [14]. A follow-up trial in Lesotho is underway to assess ART refills pro-
vided by village health workers [23], while another trial of community-based ART initiation is
underway in South Africa and Uganda [24]. ART initiation outside of health facilities may also
improve access to treatment for populations that may have difficulty accessing traditional
health services: in Tanzania, community-based ART delivery for female sex workers improved
ART initiation rates and reduced disengagement in care [25].
Out-of-facility ART initiation is another promising intervention for future WHO guidance.
Benefits may vary according to context (e.g., HIV prevalence, urban versus rural setting, HIV
testing strategy, and ART coverage). More research is needed to determine the optimal quan-
tity of ART provided at initiation and the frequency and approach to ensure adherence
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counseling and appropriate clinical review, including laboratory testing and staffing needs.
For patients with a CD4 cell count less than 200 cells/mm3, access to the WHO recommended
package of care for advanced HIV needs to be improved, and consideration should be given to
adapting the package to cover region-specific comorbidities [17].
Task sharing and decentralization
Task sharing to support ART initiation by nonphysicians has been strongly recommended by
WHO since 2013 and is supported by most national guidelines surveyed (S3 Text). However,
this recommendation is generally limited to HIV testing and counseling and initiation of first-
line ART for adults, with fewer guidelines recommending task sharing for ART initiation for
children or initiation of second-line ART.
ART coverage remains low for children—52% as of the end of 2017 [26]. Task sharing
could help ensure that lack of access to specialists does not hinder pediatric ART initiation
unless clinically indicated. Similarly, up to 3 million people are estimated to need second-line
ART in sub-Saharan Africa by 2020, but coverage is much lower [27]. Delaying or not switch-
ing regimens among people with confirmed virological failure has been partly attributed to
lack of specialists required for starting second-line ART initiation [28]. Country initiatives to
support task sharing for second-line ART initiation include a second-line prescriber exam for
doctors, clinical officers, and nurses in Malawi and remote decision support from mentorship
teams in Zimbabwe.
Task sharing also can support expanded access to key diagnostic interventions, including
HIV testing and other simple diagnostic tests. WHO recommends HIV testing by lay provid-
ers [4], and task sharing of other diagnostic tests is broadly supported by a good practice state-
ment in the WHO 2016 guidelines, which states that trained and supervised nonlaboratory
staff, including lay people, can undertake finger-prick blood collection for testing [4]. Key
essential diagnostic tests performed by lay providers could include point-of-care CD4 cell
count, preparation of dried blood spot samples for early infant diagnosis and viral load (VL),
point-of-care VL, cryptococcal antigen testing, and urine lateral flow lipoarabinomannan test-
ing for TB at peripheral sites [17]. Implementing these recommendations can be supported by
future guidelines that are more explicit about the range of interventions that can be under-
taken by less-trained health workers.
A related recommendation is the decentralization of HIV treatment and care to peripheral
health centers and community sites to increase the number of facilities providing ART, bring
care closer to where people live, and decongest hospitals. Decentralization of ART to lower-
level health centers has been widely adopted, but community ART provision remains limited
(S4 Text).
Antiretroviral delivery for stable clients
Since 2016, WHO has recommended reducing the frequency of clinic visits and ART refills for
stable clients [4]. This approach to differentiated treatment delivery is supported by major
funding agencies including The United States President’s Emergency Plan for AIDS Relief
(PEPFAR) and the Global Fund and has been adopted by a number of national guidelines
[29].
In 2016, WHO recommended reducing the frequency of clinic visits for stable ART clients
to once every 3–6 months. Data from UNAIDS up to the end of 2019 show that of 120 coun-
tries surveyed, the majority (104) have adopted these recommendations (Fig 1).
A study from Zambia found that visits every 6 months were associated with decreased
adverse outcomes (e.g., lateness or gaps in medication) and improved retention in care [30].
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Some countries recommend annual clinical visits (e.g., South Africa and Zimbabwe); there are
no data for the impact of annual visits on retention.
For children and adolescents, visits every 3 months are recommended more frequently in
national guidelines than visits every 6 months, and several countries still require monthly visits
for adolescents (S5 Text). Young children and adolescents are often evaluated monthly until
they transition to adult doses, despite evidence and guidance that children aged�2 years may
be seen every 3 months with drug dose adjustments managed appropriately [31,32].
The 2016 WHO guidelines also recommend ART refills once every 3–6 months for stable
clients, and these recommendations have also been widely adopted by the majority of coun-
tries (Fig 1 and S5 Text). In Ethiopia, 6-month refills have been rolled out with initial positive
findings [33]. A quality improvement intervention from Zambia increased the number of facil-
ities offering 3-month refills in accordance with national policy, which resulted in 20 fewer
patient visits per day in facilities receiving the intervention [34]. Since April 2019, following a
Ministry of Health directive, Zambia also has scaled up 6-month refills for stable patients.
Another study from Zambia found that patients preferred longer ART refill intervals—a
5-month interval was preferable to 3 months, which was preferable to 1 month [35,36].
Future guidance could help clarify the optimal frequency of clinic visits and ART refills.
Policies could consider accommodating patient preferences and the need to simplify and align
clinic visits and drug refills for patients with comorbidities.
Fig 1. Country policies on the frequency of clinic visits and drug refills for people who are stable on ART. Data from UNAIDS, 2019: http://lawsandpolicies.unaids.
org/ ART, antiretroviral therapy.
https://doi.org/10.1371/journal.pmed.1003028.g001
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Integrating support for adherence and retention in care
Adherence to ART is critical to ensuring successful treatment outcomes and to reducing the
risk of drug resistance. Although studies have suggested that 95% adherence is optimal, recent
studies suggest that lower levels (80%–90%) may be sufficient with newer regimens [37].
VL is the preferred way to measure adherence, and viral suppression is high: above 80%
among people retained in care [38]. Alternative approaches to assess adherence that are practi-
cal at scale in resource-limited settings include pharmacy refill records, self-reporting, and pill
counts. Although there is currently no consensus on which approach provides the most reli-
able way to identify adherence challenges, pharmacy refill records are a feasible and reliable
approach and are underutilized.
Peer counseling, adherence clubs, and mobile text messaging and reminder devices are rec-
ommended by current guidelines to support adherence and retention in care [4]. Reasons for
suboptimal adherence are multiple and similar to reasons for disengagement from care, and
some supportive interventions address both issues [39,40], suggesting that for future guidance
interventions to support adherence, retention, and reengagement in care could be considered
together as a single package.
Peer support groups
Establishing peer support groups for stable ART patients both in health facilities and in the
community fosters support and facilitates access to treatment [41]. Several models have been
piloted and have improved outcomes for patients [42–46], including for children, adolescents,
and breastfeeding women [47–49]. National HIV program managers prefer having a choice of
models that can be applied in different contexts. Future guidance could propose limited
options that would help national programs select the most appropriate model for differentiated
service delivery given contextual factors, such as HIV prevalence, ART cohort size, health
worker density, distance to health facilities, and comorbidities.
Tracing and reengagement in care
Optimal approaches are needed to trace people who disengage from care and support return
to care. Effective return to care includes rapid reinitiation of ART, clinical assessment, prophy-
laxis and management of opportunistic infections for patients with advanced HIV disease, and
VL testing to assess need for regimen switch. Counseling also should be provided to under-
stand reasons for disengagement and to offer any support required to facilitate return to care.
Tracing and reengagement programs can be effective [50,51]. A study from Uganda found
that 70% of people traced after missing a scheduled clinic visit returned to care [51]. Another
study from Kenya suggested that reengagement efforts are most effective when delivered in the
initial period after disengagement [52]. Tracing also allows for clinics to track their outcomes
more accurately and to use these outcomes for performance management.
Future guidance should recommend effective, feasible, and acceptable approaches to sup-
port tracing and reengagement with care and clarify who should perform the tracing and the
type (e.g., by telephone or home visits) and frequency of interventions. Tracing should be pri-
oritized for patients with high mortality risk, such as those who do not attend scheduled fol-
low-up visits after hospital discharge [53].
A growing number of patients presenting with advanced HIV disease had previously started
ART and then disengaged from care [54]. Guidance is needed to define what support should
be provided after a period of prolonged disengagement from care, beyond the core package of
care for patients with advanced HIV disease.
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The use of national-level unique identifiers for patients would support effective tracing
across the health system and improve return to HIV treatment as well as management for
complex cases in decentralized clinical settings, via consultation or referral.
Welcoming health services
A study from Zambia assessing patient preferences found that although longer ART refill
intervals were preferred, patients were willing to accept shorter refills to access nice (as
opposed to rude) providers [35]. This finding supports research from other studies that found
that harsh and disrespectful treatment from health providers was a reason for disengagement
for care [55–57].
Shame and fear of negative attitudes can lead people to be reluctant to return to care follow-
ing disengagement [56]. In South Africa, clinics have piloted a successful “welcome back”
counseling strategy that provides a nonjudgmental approach to reengagement in care [58].
Communicating acceptance also has encouraged reengagement in care in other settings [59].
Further research is needed to identify feasible, cost-effective approaches to improve health
worker attitudes and patient experiences of care provision.
Managing advanced HIV disease
WHO recommends a package of care for people presenting or re-presenting to care with
advanced HIV disease [17]. Baseline CD4 cell counts should be obtained to identify patients
with advanced HIV disease (defined as CD4<200 cells/mm3). Patients with advanced HIV
disease should be screened for TB and cryptococcus and provided with prophylaxis, given the
high mortality rates associated with these coinfections. Future guidance should consider
whether additional interventions should be included, especially to reduce the risk of mortality
associated with severe bacterial infections [17,60] and to identify potentially serious coinfec-
tion at an earlier stage before symptoms develop [61].
Service integration
Currently, WHO recommends service integration for common coinfections and comorbidi-
ties. These include providing both HIV and TB treatment, including TB preventive treatment
in settings with a high burden of both diseases, providing ART in settings that offer opioid sub-
stitution therapy, integrating sexually transmitted infections (STIs) and family planning ser-
vices within HIV care settings, and assessing and managing cardiovascular risk and depression
[4]. Most countries surveyed offered integrated services for TB, maternal and child health, and
STI services; integrating cancer screening and noncommunicable disease care was less com-
mon (S6 Text).
Several studies have assessed the impact of integrating care for HIV, hypertension, and dia-
betes [62], and integrating care for these conditions is recommended by some national guide-
lines. In Kenya, for example, blood pressure and glucose levels are monitored at baseline and
follow-up, and clinicians providing ART are trained to manage diabetes and hypertension;
basic screening for depression and alcohol and drug dependency is carried out routinely before
ART initiation and yearly thereafter [63]. Malawi, South Africa, and eSwatini also have imple-
mented policies for integrating HIV and noncommunicable disease care [63]. With the
increasing scale-up of differentiated service delivery models for stable patients, care for other
chronic diseases could be integrated with HIV services [64].
WHO recommends integrating family planning into ART services as a one-stop service,
and future guidance could consider integrating family planning in differentiated service deliv-
ery models for stable clients. Many countries face persistent challenges, such as lack of supplies
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and trained health workers to providing long-acting, reversible contraception options such as
implants and intrauterine devices. In Malawi, approximately 20% of women received family
planning during ART consultations in 2018, and 69% of last pregnancies were unintended,
which highlights the unmet need for family planning in women receiving ART. The high pro-
portion of women who became pregnant while using contraception was ascribed to inconsis-
tent condom usage or poor patient adherence to hormonal contraception [65]. In a partner-
supported clinic in Malawi that integrated family planning into ART services, uptake of family
planning increased from 28% to 62% [66].
Integration of HIV and noncommunicable diseases and sexual and reproductive health are
key areas for future WHO guidance to support service integration. Service integration across a
range of comorbidities should aim to align clinical follow-up and drug refill schedules as far as
possible, adapted to the reduced frequency of contact with health services for the majority of
clients who are stable on therapy.
Discussion
Recommendations for HIV service delivery in WHO guidelines have been informed by evi-
dence and experience of successful scale-up of ART across a range of settings and populations.
Key areas requiring clarification within existing recommendations include task sharing and
decentralization of services for pediatric populations and second-line ART prescription as well
as prioritization of linkage to care interventions. New areas that require guidance include com-
munity-based ART initiation, patient tracing, and reengagement of people lost to follow-up.
HIV services could consider integrating the broad range of health needs of people living
with HIV into models of care that may require less interaction with the health system while
ensuring successful long-term outcomes of HIV treatment. Country experience of implement-
ing differentiated service delivery models at scale has provided further evidence of the short-
term impact of specific models for stable clients, those who may be at risk of advanced disease,
and for specific populations. Ongoing evaluation would facilitate understanding of the net
effects of introducing differentiated service delivery models on health service requirements
and long-term outcomes for people living with HIV.
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